{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=61",
    "query": {
      "condition": "Developmental Defect",
      "page": 61
    },
    "page_size": 10
  },
  "pagination": {
    "page": 61,
    "page_size": 10,
    "total_count": 10808,
    "total_pages": 1081,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=62&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=60&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T11:37:53.092Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07080905",
      "title": "Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "138 Months",
        "maximum_age": "206 Months",
        "sex": "MALE",
        "summary": "138 Months to 206 Months · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2025-07-28",
      "completion_date": "2033-10-24",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-28T11:37:53.092Z",
      "location_count": 6,
      "location_summary": "Orange, California • San Diego, California • Gainesville, Florida + 3 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07080905"
    },
    {
      "nct_id": "NCT02084394",
      "title": "Cerebral Blood Flow During CPB During Cardiac Surgery and the Presence of Post op Delirium",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Delirium"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2013-06",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-02-09",
      "last_synced_at": "2026-10-28T11:37:53.092Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02084394"
    },
    {
      "nct_id": "NCT00125346",
      "title": "Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Tobramycin Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Years to 21 Years"
      },
      "enrollment_count": 98,
      "start_date": "2005-09",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2011-10-12",
      "last_synced_at": "2026-10-28T11:37:53.092Z",
      "location_count": 26,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Fresno, California + 23 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00125346"
    },
    {
      "nct_id": "NCT01958320",
      "title": "Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Patent Ductus Arteriosus",
        "Surgery",
        "Necrotizing Enterocolitis",
        "Intestinal Perforation"
      ],
      "interventions": [
        {
          "name": "pharmacologic treatment of the PDA",
          "type": "OTHER"
        },
        {
          "name": "no pharmacologic treatment of the PDA",
          "type": "OTHER"
        },
        {
          "name": "NSAID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Days",
        "maximum_age": "14 Days",
        "sex": "ALL",
        "summary": "5 Days to 14 Days"
      },
      "enrollment_count": 202,
      "start_date": "2013-12",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2018-11-30",
      "last_synced_at": "2026-10-28T11:37:53.092Z",
      "location_count": 13,
      "location_summary": "San Diego, California • San Francisco, California • San Jose, California + 9 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Santa Clara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01958320"
    },
    {
      "nct_id": "NCT02579759",
      "title": "Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Charcot-Marie-Tooth Disease Type 1A"
      ],
      "interventions": [
        {
          "name": "PXT3003 dose 1",
          "type": "DRUG"
        },
        {
          "name": "PXT3003 dose 2",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharnext S.C.A.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 323,
      "start_date": "2015-12",
      "completion_date": "2018-08",
      "has_results": true,
      "last_update_posted_date": "2020-02-27",
      "last_synced_at": "2026-10-28T11:37:53.092Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • New Britain, Connecticut • Gainesville, Florida + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579759"
    },
    {
      "nct_id": "NCT01521546",
      "title": "Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "eplerenone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Subha Raman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "7 Years and older · Male only"
      },
      "enrollment_count": 42,
      "start_date": "2012-02",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2016-11-08",
      "last_synced_at": "2026-10-28T11:37:53.092Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Cincinnati, Ohio • Columbus, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01521546"
    },
    {
      "nct_id": "NCT03537651",
      "title": "A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "TEZ/IVA",
          "type": "DRUG"
        },
        {
          "name": "IVA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2018-04-25",
      "completion_date": "2023-09-29",
      "has_results": true,
      "last_update_posted_date": "2024-04-19",
      "last_synced_at": "2026-10-28T11:37:53.092Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03537651"
    },
    {
      "nct_id": "NCT05996003",
      "title": "NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy",
        "Exon 44",
        "DMD"
      ],
      "interventions": [
        {
          "name": "NS-089/NCNP-02",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NS Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "14 Years",
        "sex": "MALE",
        "summary": "4 Years to 14 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2024-02-22",
      "completion_date": "2027-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-28T11:37:53.092Z",
      "location_count": 11,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05996003"
    },
    {
      "nct_id": "NCT03687242",
      "title": "Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Adrenal Hyperplasia",
        "CAH - Congenital Adrenal Hyperplasia",
        "CAH - 21-Hydroxylase Deficiency"
      ],
      "interventions": [
        {
          "name": "SPR001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spruce Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2018-09-06",
      "completion_date": "2019-08-09",
      "has_results": true,
      "last_update_posted_date": "2025-04-01",
      "last_synced_at": "2026-10-28T11:37:53.092Z",
      "location_count": 8,
      "location_summary": "Orange, California • San Diego, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03687242"
    },
    {
      "nct_id": "NCT06076642",
      "title": "A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency Diseases (PID)"
      ],
      "interventions": [
        {
          "name": "TAK-881",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2024-11-04",
      "completion_date": "2028-05-16",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-10-28T11:37:53.092Z",
      "location_count": 13,
      "location_summary": "Irvine, California • Walnut Creek, California • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06076642"
    }
  ]
}